Systemic therapy for pulmonary carcinoids.

Area of Science:

• Oncology
• Pulmonary Medicine
• Neuroendocrine Tumors

Background:

• Neuroendocrine tumors (NETs) of the lung, including typical pulmonary carcinoids (TPC), atypical pulmonary carcinoids (APC), and high-grade carcinomas, represent 25-33% of all NETs.
• The incidence and prevalence of pulmonary carcinoids (PCs) are increasing, yet robust data on systemic treatments are lacking.
• Existing treatment data are limited by small sample sizes, lack of randomized trials, and extrapolation from extrapulmonary NETs.

Purpose of the Study:

• To review and discuss current recommendations for systemic treatments in pulmonary carcinoids (PCs).
• To address the limitations in existing data and treatment guidelines for PCs.

Main Methods:

• Systematic review of existing literature and clinical guidelines.
• Discussion of current evidence and controversies in systemic therapy for PCs.

Main Results:

• Data on systemic treatments for PCs are limited, controversial, and often based on outdated or poorly designed studies.
• Conclusions are frequently extrapolated from extrapulmonary neuroendocrine tumors, and control arms may not adequately account for the indolent nature of some PCs.

Conclusions:

• There is a critical need for well-designed clinical trials to establish evidence-based systemic treatment guidelines for pulmonary carcinoids.
• Current recommendations require careful consideration of tumor behavior and available evidence due to data limitations.